Top

Published in:

01-09-2023 | Growth Factors | REVIEWS

Current Data on the Age-Related Macular Degeneration Pathophysiology: Focus on Growth Factors and Neurotrophins

Authors: A. Zh. Fursova, A. S. Derbeneva, M. A. Vasilyeva, I. F. Nikulich, M. S. Tarasov, Yu. A. Gamza, N. V. Chubar, O. G. Gusarevich, E. I. Dmitrieva, D. V. Telegina, O. S. Kozhevnikova

Published in: Advances in Gerontology | Issue 3/2023

Abstract

Age is a main risk factor for age-related macular degeneration (AMD), a complex multifactorial neurodegenerative retinal disease that is becoming the leading cause of vision loss in people over 55 years in developed countries. The risk of developing and rate of progression of AMD, as well as response to therapy, depend on the interaction of multiple genetic and environmental factors. In advanced stage, AMD is classified into dry atrophic (dry) or neovascular (wet) form. Intravitreal injection of anti-vascular endothelial growth factor agents is currently the first-line therapy for neovascular AMD. Unfortunately, therapy for dry AMD is still challenging, owing to an insufficient knowledge of the exact pathogenetic mechanisms. Considering the heterogeneity of AMD and the complexity of influencing age-dependent physiological processes, aging and immune disorders, the most realistic seems to be the further development of antiangiogenic therapy with an expansion of the range of targets, prolongation of their action and improvement of the delivery system. The neuroprotective potential of exogenous neurotrophins for retinal neurons has been proven; however, in order to develop effective drugs for the dry form of AMD based on them, it is necessary to resolve the issue of ways to effectively deliver them to the retina. In this review we discuss the current data on the AMD pathophysiology with focus on the role of vascular growth factors and neurotrophins.

Guymer, R.H. and Campbell, T.G., Age-related macular degeneration, Lancet, 2023, vol. 401, no. 10386, pp. 1459–1472. https://doi.org/10.1016/S0140-6736(22)02609-5CrossRefPubMed

Bhutto, I. and Lutty, G., Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex, Mol. Aspects Med., 2012, vol. 33, no. 4, pp. 295–317. https://doi.org/10.1016/j.mam.2012.04.005CrossRefPubMedPubMedCentral

Zaytseva, O.V., Neroeva, N.V., Okhotsimskaya, T.D., and Bobykin, E.V., Anti-VEGF therapy for neovascular age-related macular degeneration: Causes of incomplete response, Vestn. Oftalmol., 2021, vol. 137, no. 5, pp. 152–159. https://doi.org/10.17116/oftalma2021137051152CrossRefPubMed

Kauppinen, A., Paterno, J.J., Blasiak, J., Salminen, A., and Kaarniranta, K., Inflammation and its role in age-related macular degeneration, Cell Mol. Life Sci., 2016, vol. 73, no. 9, pp. 1765–1786. https://doi.org/10.1007/s00018-016-2147-8CrossRefPubMedPubMedCentral

Rozing, M.P., Durhuus, J.A., Krogh Nielsen, M., Subhi, Y., Kirkwood, T.B., Westendorp, R.G., and Sorensen, T.L., Age-related macular degeneration: A two-level model hypothesis, Prog. Retin. Eye Res., 2020, vol. 76, p. 100825. https://doi.org/10.1016/j.preteyeres.2019.100825CrossRefPubMed

Wakatsuki, Y., Shinojima, A., Kawamura, A., and Yuzawa, M., Correlation of aging and segmental choroidal thickness measurement using swept source optical coherence tomography in healthy eyes, PLoS One, 2015, vol. 10, no. 12, p. e0144156. https://doi.org/10.1371/journal.pone.0144156CrossRefPubMedPubMedCentral

Lee, K.S., Lin, S., Copland, D.A., Dick, A.D., and Liu, J., Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration, J. Neuroinflammation, 2018, vol. 18, no. 1, p. 32. https://doi.org/10.1186/s12974-021-02088-0CrossRef

Mitre, M., Mariga, A., and Chao, M.V., Neurotrophin signalling: Novel insights into mechanisms and pathophysiology, Clin. Sci. (Lond.), 2017, vol. 131, no. 1, pp. 13–23. https://doi.org/10.1042/CS20160044CrossRefPubMed

Boyer, N.P., Higbee, D., Currin, M.B., Blakeley, L.R., Chen, C., Ablonczy, Z., Crouch, R.K., and Koutalos, Y., Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: Their origin is 11-cis-retinal, J. Biol. Chem., 2012, vol. 287, no. 26, pp. 22 276–22 286. https://doi.org/10.1074/jbc.M111.329235CrossRef

10.

Liu, J., Itagaki, Y., Ben-Shabat, S., Nakanishi, K., and Sparrow, J.R., The biosynthesis of A2E, a fluorophore of aging retina, involves the formation of the precursor, A2-PE, in the photoreceptor outer segment membrane, J. Biol. Chem., 2000, vol. 275, no. 38, pp. 29 354–29 360. https://doi.org/10.1074/jbc.M910191199CrossRef

11.

Macchioni, L., Chiasserini, D., Mezzasoma, L., Davidescu, M., Orvietani, P.L., Fettucciari, K., Salviati, L., Cellini, B., and Bellezza, I., Crosstalk between long-term sublethal oxidative stress and detrimental inflammation as potential drivers for age-related retinal degeneration, Antioxidants, 2020, vol. 10, no. 1, p. 25, https://doi.org/10.3390/antiox10010025CrossRefPubMedPubMedCentral

12.

Kaarniranta, K., Uusitalo, H., Blasiak, J., Felszeghy, S., Kannan, R., Kauppinen, A., Salminen, A., Sinha, D., and Ferrington, D., Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration, Prog. Retin. Eye Res., 2020, vol. 79, p. 100858. https://doi.org/10.1016/j.preteyeres.2020.100858CrossRefPubMedPubMedCentral

13.

Kim, J., Lee, Y.J., and Won, J.Y., Molecular mechanisms of retinal pigment epithelium dysfunction in age-related macular degeneration, Int. J. Mol. Sci., 2021, vol. 22, no. 22, p. 12 298. https://doi.org/10.3390/ijms222212298CrossRef

14.

Minasyan, L., Sreekumar, P.G., Hinton, D.R., and Kannan, R., Protective mechanisms of the mitochondrial-derived peptide humanin in oxidative and endoplasmic reticulum stress in RPE cells, Oxid. Med. Cell. Longev., 2017, p. 1675230. https://doi.org/10.1155/2017/1675230

15.

Blasiak, J., Pawlowska, E., Szczepanska, J., and Kaarniranta, K., Interplay between autophagy and the ubiquitin–proteasome system and its role in the pathogenesis of age-related macular degeneration, Int. J. Mol. Sci., 2019, vol. 20, no. 1, p. 210. https://doi.org/10.3390/ijms20010210CrossRefPubMedPubMedCentral

16.

Telegina, D.V., Kozhevnikova, O.S., and Kolosova, N.G., Molecular mechanisms of cell death in retina during development of age-related macular degeneration, Adv. Gerontol., 2017, vol. 7, pp. 17–24. https://doi.org/10.1134/S2079057017010155CrossRef

17.

Kaarniranta, K., Tokarz, P., Koskela, A., Paterno, J., and Blasiak, J., Autophagy regulates death of retinal pigment epithelium cells in age-related macular degeneration, Cell Biol. Toxicol., 2017, vol. 33, no. 2, pp. 113–128. https://doi.org/10.1007/s10565-016-9371-8CrossRefPubMed

18.

Hanus, J., Anderson, C., and Wang, S., RPE necroptosis in response to oxidative stress and in AMD, Ageing Res. Rev., 2015, vol. 24, no. Pt-B, pp. 286–298. https://doi.org/10.1016/j.arr.2015.09.002

19.

Chen, M., Glenn, J.V., Dasari, S., McVicar, C., Ward, M., Colhoun, L., Quinn, M., Bierhaus, A., Xu, H., and Stitt, A.W., RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization, PLoS One, 2014, vol. 9, no. 2, p. e89548. https://doi.org/10.1371/journal.pone.0089548CrossRefPubMedPubMedCentral

20.

Geerlings, M.J., de Jong, E.K., and den Hollander, A.I., The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment, Mol. Immunol., 2017, vol. 84, pp. 65–76. https://doi.org/10.1016/j.molimm.2016.11.016

21.

Mullins, R.F., Schoo, D.P., Sohn, E.H., Flamme-Wiese, M.J., Workamelahu, G., Johnston, R.M., Wang, K., Tucker, B.A., and Stone, E.M., The membrane attack complex in aging human choriocapillaris: Relationship to macular degeneration and choroidal thinning, Am. J. Pathol., 2014, vol. 184, no. 11, pp. 3142–3153. https://doi.org/10.1016/j.ajpath.2014.07.017CrossRefPubMedPubMedCentral

22.

Lynch, A.M., Mandava, N., Patnaik, J.L., Frazer-Abel, A.A., Wagner, B.D., Palestine, A.G., Mathias, M.T., Siringo, F.S., Cathcart, J.N., and Holers, V.M., Systemic activation of the complement system in patients with advanced age-related macular degeneration, Eur. J. Ophthalmol., 2020, vol. 30, no. 5, pp. 1061–1068. https://doi.org/10.1177/1120672119857896CrossRefPubMed

23.

Kozhevnikova, O.S., Fursova, A.Z., Derbeneva, A.S., Nikulich, I.F., Tarasov, M.S., Devyatkin, V.A., Rumyantseva, Y.V., Telegina, D.V., and Kolosova, N.G., Association between polymorphisms in CFH, ARMS2, CFI, and C3 genes and response to anti-VEGF treatment in neovascular age-related macular degeneration, Biomedicines, 2022, vol. 10, no. 7, p. 1658. https://doi.org/10.3390/biomedicines10071658CrossRefPubMedPubMedCentral

24.

Cao, S., Ko, A., Partanen, M., Pakzad-Vaezi, K., Merkur, A.B., Albiani, D.A., Kirker, A.W., Wang, A., Cui, J.Z., Forooghian, F., and Matsubara, J.A., Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration, Am. J. Ophthalmol., 2013, vol. 156, no. 6, pp. 1176–1183. https://doi.org/10.1016/j.ajo.2013.08.003CrossRefPubMedPubMedCentral

25.

Espinosa-Heidmann, D.G., Suner, I.J., Hernandez, E.P., Monroy, D., Csaky, K.G., and Cousins, S.W., Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization, Invest. Ophthalmol. Vis. Sci., 2003, vol. 44, no. 8, pp. 3586–3592. https://doi.org/10.1167/iovs.03-0038CrossRefPubMed

26.

Zhou, J., He, S., Zhang, N., Spee, C., Zhou, P., Ryan, S.J., Kannan, R., and Hinton, D.R., Neutrophils compromise retinal pigment epithelial barrier integrity, J. Biomed. Biotechnol., 2010, vol. 2010, p. 289360. https://doi.org/10.1155/2010/289360CrossRefPubMedPubMedCentral

27.

Zhao, Z., Liang, Y., Liu, Y., Xu, P., Flamme-Wiese, M.J., Sun, D., Sun, J., Mullins, R.F., Chen, Y., and Cai, J., Choroidal γδ T cells in protection against retinal pigment epithelium and retinal injury, FASEB J., 2017, vol. 31, no. 11, pp. 4903–4916. https://doi.org/10.1096/fj.201700533R

28.

Ferrara, N., Mass, R.D., Campa, C., and Kim, R., Targeting VEGF-A to treat cancer and age-related macular degeneration, Annu. Rev. Med., 2007, vol. 58, pp. 491–504. https://doi.org/10.1146/annurev.med.58.061705.145635CrossRefPubMed

29.

de Oliveira Dias, J.R., Rodrigues, E.B., Maia, M., Magalhaes, O., Jr., Penha, F.M., and Farah, M.E., Cytokines in neovascular age-related macular degeneration: Fundamentals of targeted combination therapy, Br. J. Ophthalmol., 2011, vol. 95, no. 12, pp. 1631–1637. https://doi.org/10.1136/bjo.2010.186361CrossRefPubMed

30.

Ciulla, T.A. and Rosenfeld, P.J., Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration, Curr. Opin. Ophthalmol., 2009, vol. 20, no. 3, pp. 158–165. https://doi.org/10.1097/ICU.0b013e32832d25b3CrossRefPubMed

31.

Apte, R.S., Chen, D.S., and Ferrara, N., VEGF in signaling and disease: Beyond discovery and development, Cell, 2019, vol. 176, no. 6, pp. 1248–1264. https://doi.org/10.1016/j.cell.2019.01.021CrossRefPubMedPubMedCentral

32.

Cao, Y., Positive and negative modulation of angiogenesis by VEGFR1 ligands, Sci. Signal., 2009, vol. 2, no. 59, p. re1. https://doi.org/10.1126/scisignal.259re1CrossRefPubMed

33.

Klettner, A., Kaya, L., Flach, J., Lassen, J., Treumer, F., and Roider, J., Basal and apical regulation of VEGF-A and placenta growth factor in the RPE/choroid and primary RPE, Mol. Vis., 2015, vol. 21, pp. 736–748.PubMedPubMedCentral

34.

Arjunan, P., Lin, X., Tang, Z., et al., VEGF-B is a potent antioxidant, Proc. Natl. Acad. Sci. U. S. A., 2018, vol. 115, no. 41, pp. 10351–10356. https://doi.org/10.1073/pnas.1801379115CrossRefPubMedPubMedCentral

35.

Li, X., Kumar, A., Zhang, F., Lee, C., and Tang, Z., Complicated life, complicated VEGF-B, Trends Mol. Med., 2012, vol. 18, no. 2, pp. 119–127. https://doi.org/10.1016/j.molmed.2011.11.006CrossRefPubMed

36.

Zhong, X., Huang, H., Shen, J., Zacchigna, S., Zentilin, L., Giacca, M., and Vinores, S.A., Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation, Mol Vis., 2011, vol. 17, pp. 492–507.PubMedPubMedCentral

37.

Zhang, F., Tang, Z., Hou, X., et al., VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis, Proc. Natl. Acad. Sci. U. S. A., 2009, vol. 106, no. 15, pp. 6152–6157. https://doi.org/10.1073/pnas.0813061106CrossRefPubMedPubMedCentral

38.

Uemura, A., Fruttiger, M., D’Amore, P.A., De Falco, S., Joussen, A.M., Sennlaub, F., Brunck, L.R., Johnson, K.T., Lambrou, G.N., Rittenhouse, K.D., and Langmann, T., VEGFR1 signaling in retinal angiogenesis and microinflammation, Prog. Retin. Eye Res., 2021, vol. 84, 100954. https://doi.org/10.1016/j.preteyeres.2021.100954CrossRefPubMedPubMedCentral

39.

Dugel, P.U., Boyer, D.S., Antoszyk, A.N., Steinle, N.C., Varenhorst, M.P., Pearlman, J.A., Gillies, M.C., Finger, R.P., Baldwin, M.E., and Leitch, I.M., Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration, Ophthalmol. Retina, 2020, vol. 4, no. 3, pp. 250–263. https://doi.org/10.1016/j.oret.2019.10.008CrossRefPubMed

40.

Cunningham, F., Van Bergen, T., Canning, P., Lengyel, I., Feyen, J.H.M., and Stitt, A.W., The placental growth factor pathway and its potential role in macular degenerative disease, Curr Eye Res., 2019, vol. 44, no. 8, pp. 813–822. https://doi.org/10.1080/02713683.2019.1614197CrossRefPubMed

41.

Dewerchin, M. and Carmeliet, P., PlGF: A multitasking cytokine with disease-restricted activity, Cold Spring Harb. Perspect. Med., 2012, vol. 2, no. 8, p. a011056.https://doi.org/10.1101/cshperspect.a011056CrossRefPubMedPubMedCentral

42.

De Falco, S., The discovery of placenta growth factor and its biological activity, Exp. Mol. Med., 2012, vol. 44, no. 1, pp. 1–9. https://doi.org/10.3858/emm.2012.44.1.025CrossRefPubMedPubMedCentral

43.

Patel, P. and Sheth, V., New and innovative treatments for neovascular age-related macular degeneration (nAMD), J. Clin. Med., 2021, vol. 10, no. 11, p. 2436. https://doi.org/10.3390/jcm10112436CrossRefPubMedPubMedCentral

44.

Camby, I., Le Mercier, M., Lefranc, F., and Kiss, R., Galectin-1: A small protein with major functions, Glycobiology, 2006, vol. 16, no. 11, pp. 137R–157R. https://doi.org/10.1093/glycob/cwl025CrossRefPubMed

45.

Kanda, A., Noda, K., Saito, W., and Ishida, S., Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy, Sci. Rep., 2015, vol. 5, p. 17946. https://doi.org/10.1038/srep17946CrossRefPubMedPubMedCentral

46.

Hollborn, M., Tenckhoff, S., Seifert, M., Kohler, S., Wiedemann, P., Bringmann, A., and Kohen, L., Human retinal epithelium produces and responds to placenta growth factor, Graefes Arch. Clin. Exp. Ophthalmol., 2006, vol. 244, no. 6, pp. 732–741. https://doi.org/10.1007/s00417-005-0154-9CrossRefPubMed

47.

Rakic, J.M., Lambert, V., Devy, L., Luttun, A., Carmeliet, P., Claes, C., Nguyen, L., Foidart, J.M., Noel, A., and Munaut, C., Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization, Invest. Ophthalmol. Vis. Sci., 2003, vol. 44, no. 7, pp. 3186–3193. https://doi.org/10.1167/iovs.02-1092CrossRefPubMed

48.

Motohashi, R., Noma, H., Yasuda, K., Kotake, O., Goto, H., and Shimura, M., Dynamics of inflammatory factors in aqueous humor during ranibizumab or aflibercept treatment for age-related macular degeneration, Ophthalmic. Res., 2017, vol. 58, no. 4, pp. 209–216. https://doi.org/10.1159/000478705CrossRefPubMed

49.

Pongsachareonnont, P., Mak, M.Y.K., Hurst, C.P., and Lam, W.C., Neovascular age-related macular degeneration: Intraocular inflammatory cytokines in the poor responder to ranibizumab treatment, Clin. Ophthalmol., 2018, vol. 12, pp. 1877–1885. https://doi.org/10.2147/OPTH.S171636CrossRefPubMedPubMedCentral

50.

Heier, J.S., Singh, R.P., Wykoff, C.C., Csaky, K.G., Lai, T.Y.Y., Loewenstein, A., Schlottmann, P.G., Paris, L.P., Westenskow, P.D., and Quezada-Ruiz, C., The Angiopoietin/Tie pathway in retinal vascular diseases: A review, Retina, 2021, vol. 41, no. 1, pp. 1–19. https://doi.org/10.1097/IAE.0000000000003003CrossRefPubMed

51.

Lee, J., Park, D.Y., Park, D.Y., Park, I., Chang, W., Nakaoka, Y., Komuro, I., Yoo, O.J., and Koh, G.Y., Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage, Invest. Ophthalmol. Vis. Sci., 2014, vol. 55, no. 4, pp. 2191–2199. https://doi.org/10.1167/iovs.14-13897CrossRefPubMed

52.

Hussain, R.M., Neiweem, A.E., Kansara, V., Harris, A., and Ciulla, T.A., Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease, Expert Opin. Investig. Drugs, 2019, vol. 28, no. 10, pp. 861–869. https://doi.org/10.1080/13543784.2019.1667333CrossRefPubMed

53.

Desideri, L.F., Traverso, C.E., and Nicolò, M., The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases, Expert Opin. Ther. Targets, 2022, vol. 26, no. 2, pp. 145–154. https://doi.org/10.1080/14728222.2022.2036121CrossRef

54.

Frye, M., Dierkes, M., Küppers, V., Vockel, M., Tomm, J., Zeuschner, D., Rossaint, J., Zarbock, A., Koh, G.Y., Peters, K., Nottebaum, A.F., and Vestweber, D., Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin, J. Exp. Med., 2015, vol. 212, no. 13, pp. 2267–2287. https://doi.org/10.1084/jem.20150718CrossRefPubMedPubMedCentral

55.

Campochiaro, P.A. and Peters, K.G., Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema, Curr. Diab. Rep., 2016, vol. 16, no. 12, p. 126. https://doi.org/10.1007/s11892-016-0816-5CrossRefPubMed

56.

Wubben, T.J., Zacks, D.N., and Besirli, C.G., Retinal neuroprotection: Current strategies and future directions, Curr. Opin. Ophthalmol., 2019, vol. 30, no. 3, pp. 199–205. https://doi.org/10.1097/ICU.0000000000000558CrossRefPubMed

57.

Garcia, T.B., Hollborn, M., and Bringmann, A., Expression and signaling of NGF in the healthy and injured retina, Cytokine Growth Factor Rev., 2017, vol. 34, pp. 43–57. https://doi.org/10.1016/j.cytogfr.2016.11.005CrossRefPubMed

58.

Balzamino, B.O., Esposito, G., Marino, R., Keller, F., and Micera, A., NGF expression in reelin-deprived retinal cells: A potential neuroprotective effect, Neuromolecular Med., 2015, vol. 17, no. 3, pp. 314–325.https://doi.org/10.1007/s12017-015-8360-z35

59.

Taylor, S., Srinivasan, B., Wordinger, R.J., and Roque, R.S., Glutamate stimulates neurotrophin expression in cultured Muller cells, Brain Res. Mol. Brain Res., 2003, vol. 111, nos. 1–2, pp. 189–197. https://doi.org/10.1016/S0169-328X(03)00030-5

60.

Jansen, P., Giehl, K., Nyengaard, J.R., Teng, K., Lioubinski, O., Sjoegaard, S.S., Breiderhoff, T., Gotthardt, M., Lin, F., Eilers, A., Petersen, C.M., Lewin, G.R., Hempstead, B.L., Willnow, T.E., and Nykjaer, A., Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury, Nat. Neurosci., 2007, vol. 10, no. 11, pp. 1449–1457. https://doi.org/10.1038/nn2000CrossRefPubMed

61.

Harada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L.F., and Wada, K., Microglia–Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration, J. Neurosci., 2002, vol. 22, no. 21, pp. 9228–9236. https://doi.org/10.1523/JNEUROSCI.22-21-09228.2002CrossRefPubMedPubMedCentral

62.

Srinivasan, B., Roque, C.H., Hempstead, B.L., Al-Ubaidi, M.R., and Roque, R.S., Microglia-derived pronerve growth factor promotes photoreceptor cell death via p75 neurotrophin receptor, J. Biol. Chem., 2004, vol. 279, no. 40, pp. 41 839–41 845. https://doi.org/10.1074/jbc.M402872200CrossRef

63.

Vogler, S., Hollborn, M., Berk, B.A., Pannicke, T., Seeger, J., Wiedemann, P., Reichenbach, A., and Bringmann, A., Ischemic regulation of brain-derived neurotrophic factor-mediated cell volume and TrkB expression in glial (Müller) and bipolar cells of the rat retina, Graefes Arch. Clin. Exp. Ophthalmol., 2016, vol. 254, no. 3, pp. 497–503. https://doi.org/10.1007/s00417-015-3250-5CrossRefPubMed

64.

Grishanin, R.N., Yang, H., Liu, X., Donohue-Rolfe, K., Nune, G.C., Zang, K., Xu, B., Duncan, J.L., Lavail, M.M., Copenhagen, D.R., and Reichardt, L.F., Retinal TrkB receptors regulate neural development in the inner, but not outer, retina, Mol. Cell Neurosci., 2008, vol. 38, no. 3, pp. 431–443. https://doi.org/10.1016/j.mcn.2008.04.004CrossRefPubMedPubMedCentral

65.

Espinet, C., Gonzalo, H., Fleitas, C., Menal, M.J., and Egea, J., Oxidative stress and neurodegenerative diseases: A neurotrophic approach, Curr. Drug Targets, 2015, vol. 16, no. 1, pp. 20–30. https://doi.org/10.2174/1389450116666150107153233CrossRefPubMed

66.

Kimura, A., Namekata, K., Guo, X., Harada, C., and Harada, T., Neuroprotection, growth factors and BDNF-TRKB signalling in retinal degeneration, Int. J. Mol. Sci., 2016, vol. 17, no. 9, p. 1584. https://doi.org/10.3390/ijms17091584CrossRefPubMedPubMedCentral

67.

Tekin, I.M., Sekeroglu, M.A., Demirtas, C., Tekin, K., Doguizi, S., Bayraktar, S., and Yilmazbas, P., Brain-derived neurotrophic factor in patients with age-related macular degeneration and its correlation with retinal layer thicknesses, Invest. Ophthalmol. Vis. Sci., 2018, vol. 59, no. 7, pp. 2833–2840. https://doi.org/10.1167/iovs.18-24030CrossRefPubMed

68.

Tirassa, P., Rosso, P., and Iannitelli, A., Ocular nerve growth factor (NGF) and NGF eye drop application as paradigms to investigate ngf neuroprotective and reparative actions, Methods Mol. Biol., 2018, vol. 1727, pp. 19–38. https://doi.org/10.1007/978-1-4939-7571-6_2CrossRefPubMed

69.

Mitra, S., Behbahani, H., and Eriksdotter, M., Innovative therapy for Alzheimer’s Disease—with focus on biodelivery of NGF, Front. Neurosci., 2019, vol. 13, p. 38. https://doi.org/10.3389/fnins.2019.00038CrossRefPubMedPubMedCentral

70.

Abed, E., Corbo, G., and Falsini, B., Neurotrophin family members as neuroprotectants in retinal degenerations, BioDrugs, 2015, vol. 29, no. 1, pp. 1–13. https://doi.org/10.1007/s40259-014-0110-5CrossRefPubMed

71.

Rocco, M.L. and Balzamino, B.O., Petrocchi Passeri, P., Micera, A., and Aloe, L., Effect of purified murine NGF on isolated photoreceptors of a rodent developing retinitis pigmentosa, PLoS One, 2015, vol. 10, no. 4, p. e0124810. https://doi.org/10.1371/journal.pone.0124810CrossRefPubMedPubMedCentral

72.

Falsini, B., Iarossi, G., Chiaretti, A., Ruggiero, A., Manni, L., Galli-Resta, L., Corbo, G., and Abed, E., NGF eye-drops topical administration in patients with retinitis pigmentosa, a pilot study, J. Transl. Med., 2016, vol. 14, p. 8. https://doi.org/10.1186/s12967-015-0750-3CrossRefPubMedPubMedCentral

73.

Daly, C., Ward, R., Reynolds, A.L., Galvin, O., Collery, R.F., and Kennedy, B.N., Brain-derived neurotrophic factor as a treatment option for retinal degeneration, Adv. Exp. Med. Biol., 2018, vol. 1074, pp. 465–471. https://doi.org/10.1007/978-3-319-75402-4_57CrossRefPubMed

74.

Weber, A.J. and Harman, C.D., BDNF treatment and extended recovery from optic nerve trauma in the cat, Investig. Ophthalmol. Vis. Sci., 2013, vol. 54, no. 10, pp. 6594–6604. https://doi.org/10.1167/iovs.13-12683CrossRef

75.

Feng, L., Puyang, Z., Chen, H., Liang, P., Troy, J.B., and Liu, X., Overexpression of brain-derived neurotrophic factor protects large retinal ganglion cells after optic nerve crush in mice, eNeuro, 2017, vol. 4, no. 1, p. ENEURO.0331-16.2016. https://doi.org/10.1523/ENEURO.0331-16.2016

76.

Afarid, M., Torabi-Nami, M., and Zare, B., Neuroprotective and restorative effects of the brain-derived neurotrophic factor in retinal diseases, J. Neurol. Sci., 2016, vol. 363, pp. 43–50. https://doi.org/10.1016/j.jns.2016.02.024CrossRefPubMed

Title: Current Data on the Age-Related Macular Degeneration Pathophysiology: Focus on Growth Factors and Neurotrophins
Authors: A. Zh. Fursova
A. S. Derbeneva
M. A. Vasilyeva
I. F. Nikulich
M. S. Tarasov
Yu. A. Gamza
N. V. Chubar
O. G. Gusarevich
E. I. Dmitrieva
D. V. Telegina
O. S. Kozhevnikova
Publication date: 01-09-2023
Publisher: Pleiades Publishing
Keywords: Growth Factors
Growth Factors
Macular Degeneration
Published in: Advances in Gerontology / Issue 3/2023
Print ISSN: 2079-0570
Electronic ISSN: 2079-0589
DOI: https://doi.org/10.1134/S2079057024600162

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Mechanisms of Neurocognitive Adaptation during Aging Process

The Rate of Aging and Its Association with Risk Factors of Cardiovascular Diseases

The Role of the Serotonin Pathway of Tryptophan Metabolism in the Development of Neuroinflammation in Alzheimer’s Disease

Vascular Aging and Telomere Biology: On the Role of Vitamin D3 Deficiency

Demographic Indicators of Probability Models

Age-Related Changes and Loss of Damage Resistance of Kidney Tissue: The Role of a Decrease in the Number of Kidney Resident Progenitor Cells

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage